Arvee Laboratories (India) Ltd (ARVEE) — shareholding pattern, promoter holding, financials and share price
About Arvee Laboratories (India) Ltd (ARVEE)
Arvee Laboratories (India) Ltd operates in the Other Industrial Products industry, within the Capital Goods sector. It trades on the NSE as ARVEE and on the BSE under scrip code 535050. Its ISIN is INE006Z01016.
Incorporated in 2012, Arvee Laboratories India Ltd manufactures specialized chemicals [1]
Arvee Laboratories (India) Limited primarily manufactures specialized chemicals for various industrial applications, including Thiophene and Isophthalic acid derivatives.
Founded in 2012 and converted into a public company in 2017, Arvee has swiftly established itself as a credible international vendor, having passed rigorous quality audits.
Listed peers in Other Industrial Products: Globe International Carriers Ltd, Sadhav Shipping Ltd, Expo Engineering and Projects Ltd, Neochem Bio Solutions Ltd, De Neers Tools Ltd, Envirotech Systems Ltd.
Valuation & Returns
10 Jul 2026At ₹160 a share on 10 Jul 2026, Arvee Laboratories (India) Ltd (ARVEE) was valued at a price-to-earnings ratio of 69.69x against an industry P/E of 37x and a price-to-book of 5.64x on a book value of ₹28.37 per share as of Mar 2025. Solomo computes return on equity of 8.09% and return on capital employed of 8.21% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 69.69x
- Industry P/E
- 37x
- P/B
- 5.64x
- EPS (TTM)
- ₹2.3
- Book value / share
- ₹28.37
- ROE
- 8.09%
- ROCE
- 8.21%
- ROA
- 6.73%
- Debt / equity
- 0.03x
- Dividend yield
- 0%
- EBITDA margin
- 12.31%
- 52-week range
- ₹129.11 – ₹290.78
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Arvee Laboratories (India) Ltd (ARVEE) reported revenue of ₹31.51 crore, net profit of ₹2.53 crore and earnings per share of ₹2.3. That compares with revenue of ₹38.49 crore and net profit of ₹2.15 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹10.8 crore and net profit ₹0.52 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 40.33 | 61.35 | 30.35 | 38.49 | 31.51 |
| Net profit (₹ cr) | 2.57 | 4.12 | 1.05 | 2.15 | 2.53 |
| EPS (₹) | 2.33 | 3.74 | 0.95 | 1.95 | 2.3 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | -3.26% | -1.54% | 26.82% |
| Profit growth | -1.36% | -5.86% | 104.76% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 73.5% of Arvee Laboratories (India) Ltd (ARVEE) (unchanged from the previous quarter). Market capitalisation was ₹176 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2018.
Largest disclosed public shareholders in Jun 2026: GITABEN DINEHSBHAI PATEL 9.98%, DEVAL PRANAV PATEL 5.19%, JASHBHAI PATEL 4.79%, MADHUBEN JASHBHAI PATEL 3.7%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 73.5% | - | - | - | - |
| Mar 2026 | 73.5% | - | - | - | - |
| Dec 2025 | 73.5% | - | - | - | - |
| Sep 2025 | 73.5% | - | - | - | - |
| Jun 2025 | 73.5% | - | - | - | - |
| Mar 2025 | 73.5% | - | - | - | - |
| Dec 2024 | 73.5% | - | - | - | - |
| Sep 2024 | 73.5% | - | - | - | - |